Skip to main content
Log in

Afatinib/erlotinib

Rash, paronychia and diarrhoea: 3 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Lewis PJ, et al. Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA). Lung Cancer 103 (Suppl. 1): S34 abstr. 71, Jan 2017 [abstract] - United Kingdom

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib/erlotinib. Reactions Weekly 1694, 21 (2018). https://doi.org/10.1007/s40278-018-43423-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-43423-x

Navigation